Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ICCC stock hub

ImmuCell Corporation has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ICCCis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

72.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ICCC

In the news

Latest news · ICCC

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-3.8

P25 -105.6P50 -46.5P75 -3.1

ROIC6.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ICCC market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

221

Groups with data

Currency

USD

Showing 221 of 221 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000811641
Company name	ImmuCell Corporation
Country	United States
Country code	US
Cusip	452525306
Employees	73
Employees Change	-2%
Employees Change Percent	-2.67
Enterprise value	$82.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1987-04-30
Isin	US4525253062
Last refreshed	2026-05-10
Market cap	$72.8M
Market cap category	Micro-Cap
Price	$8.05
Price currency	USD
Rev Per Employee	378,687.32x
Sector	Healthcare
Sic	2835
Symbol	ICCC
Website	https://immucell.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.43%
EV/EBIT	33.57x
EV/EBITDA	15.87x
EV/FCF	67.12x
EV/Sales	2.97x
FCF yield	1.68%
P/B ratio	2.69x
P/S ratio	2.63x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	8.86%
EBITDA Margin	18.73%
FCF margin	4.43%
Gross margin	41.4%
Gross Profit	$11.4M
Gross Profit Growth	44.13%
Gross Profit Growth Q	2.77%
Gross Profit Growth3 Y	11.58%
Gross Profit Growth5 Y	10.77%
Net Income	$-1M
Net Income Growth Years	2%
Pretax Margin	-3.72%
Profit Margin	-3.76%
Profit Per Employee	$-14,247
ROA	3.49
Roa5y	-1.64
ROCE	6.35
ROE	-3.81
Roe5y	-8.21
ROIC	6.45
Roic5y	-3.03

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	2.18%
Cagr15y	4.17%
Cagr1y	55.15%
Cagr20y	1.5%
Cagr3y	17.99%
Cagr5y	-4.25%
EPS Growth Years	2
OCF Growth	591.61%
OCF Growth10 Y	-1.57%
OCF Growth5 Y	13.48%
Revenue Growth	4.35x
Revenue Growth Q	-1.61x
Revenue Growth Years	2x
Revenue Growth3 Y	14.19x
Revenue Growth5 Y	12.5x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.63
Assets	$42.5M
Cash	$3.8M
Current Assets	$16.9M
Current Liabilities	$4M
Debt	$13.2M
Debt EBITDA	$2.33
Debt Equity	$0.49
Debt FCF	$10.77
Equity	$27.1M
Interest Coverage	4.96
Liabilities	$15.5M
Long Term Assets	$25.6M
Long Term Liabilities	$11.5M
Net Cash	$-9.4M
Net Cash By Market Cap	$-12.89
Net Debt EBITDA	$1.81
Net Debt Equity	$0.35
Net Debt FCF	$7.66
Tangible Book Value	$27M
Tangible Book Value Per Share	$2.98
WACC	6.4

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.26
Inventory Turnover	1.98
Net Working Capital	$10.9M
Quick ratio	1.82
Working Capital	$13M
Working Capital Turnover	$2.34

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-10.52%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	24.04%
1Y total return	55.11%
200-day SMA	6.38
3Y total return	64.29%
50-day SMA	7.14
50-day SMA vs 200-day SMA	50over200
5Y total return	-19.5%
All Time High	13.2
All Time High Change	-39.02%
All Time High Date	2021-01-29
All Time Low	1
All Time Low Change	705%
All Time Low Date	1992-05-01
ATR	0.35
Beta	0.5
Beta1y	0.08
Beta2y	-0.17
Ch YTD	30.89
High	8.65
High52	9.08
High52 Date	2026-05-06
High52ch	-11.34%
Low	7.97
Low52	4.52
Low52 Date	2025-11-21
Low52ch	78.1%
Ma50ch	12.76%
Price vs 200-day SMA	26.18%
RSI	53.4
RSI Monthly	62.32
RSI Weekly	63.13
Sharpe ratio	0.96x
Sortino ratio	1.65
Total Return	-10.52%
Tr YTD	30.89
Tr15y	84.63%
Tr1m	21.97%
Tr1w	-7.79%
Tr3m	29.01%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$2.4M
Operating Income Growth Q	19.42
Operating margin	8.86

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6,004,883%
Float Percent	66.38%
Net Borrowing	-1,479,202
Shares Insiders	28.07%
Shares Institutions	18.41%
Shares Out	9,046,799
Shares Qo Q	1.6%
Shares Yo Y	10.52%
Short Float	0.45%
Short Ratio	1.17
Short Shares	0.3

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$928,982
Average Volume	27,230.35x
Bv Per Share	2.99
CAPEX	$-1.3M
Ch10y	24.04
Ch15y	84.63
Ch1m	21.97
Ch1w	-7.79
Ch1y	55.11
Ch20y	34.62
Ch3m	29.01
Ch3y	64.29
Ch5y	-19.5
Ch6m	31.97
Change	-4.96%
Change From Open	-5.18
Close	8.47
Days Gap	0.24
Depreciation Amortization	2,729,601
Dollar Volume	186,751
Earnings Date	2026-05-14
Earnings Time	amc
EBIT	$2.4M
EBITDA	$5.2M
EPS	$-0.12
F Score	7
FCF	$1.2M
FCF EV Yield	1.49x
FCF Per Share	$0.14
Financing CF	-1,212,386
Fiscal Year End	December
Founded	1,982
Goodwill	95,557
Income Tax	$11,570
Investing CF	-1,214,307
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-04
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-30
Ma150	6.43
Ma150ch	25.29%
Ma20	8.15
Ma20ch	-1.17%
Net CF	48,599
Next Earnings Date	2026-05-14
Open	8.49
Optionable	No
P FCF Ratio	59.46
P OCF Ratio	29.42
Position In Range	11.76
Post Close	8.05
Postmarket Change Percent	1.87
Postmarket Price	$8.2
Ppne	25,454,322
Price Date	2026-05-08
Price EBITDA	$14.06
Ptbv Ratio	2.7
Relative Volume	0.85x
Revenue	27,644,174x
SBC By Revenue	1.07x
Share Based Comp	295,871
Tax By Revenue	0.04x
Tr20y	34.62%
Tr6m	31.97%
Us State	Maine
Volume	23,198.9
Z Score	2.73

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ICCC pay a dividend?

Capital-return profile for this ticker.

Performance

ICCC stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ICCC?

Insider, institutional, and short-interest positioning.

Institutional ownership

+18.4%

Float: +66.4% of shares outstanding

Insider ownership

+28.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ICCC momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.4

Neutral momentum band

Price vs 200-day MA

+26.2%

50/200-day relationship not available

Beta (5Y)

0.50

Less volatile than the market

Sharpe ratio

0.96

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ICCC

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ICCC stock rating?

ImmuCell Corporation is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ICCC analysis?

The full report lives at /stocks/ICCC/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ICCC?

The latest report frames ICCC around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ICCC page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.